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Abstract We examined the biological effects of the ceramide
analogues (1S,2R)-2-N-myristoylamino-1-phenyl-1-propanol (D-
e-MAPP) and (1R,2R)-2-N-myristoylamino-1-(4-nitrophenyl)-
1,3-propandiol (D-NMAPPD) on human HaCaT keratinocytes
and human melanoma cells. We could demonstrate that D-e-
MAPP and D-NMAPPD are able to suppress acid ceramidase
activity. The elevation of the endogenous level of ceramide is
followed by induction of apoptosis and suppression of prolifera-
tion in HaCaT keratinocytes. Moreover, we recently identified a
group of human melanoma cell populations which are hetero-
geneously susceptible to C2-ceramide-mediated apoptosis. Stu-
dies with these melanoma cells revealed correlation between
ceramide-mediated apoptosis and D-NMAPPD-induced apopto-
sis, confirming the effect of this inhibitor on ceramide signaling
in human melanoma cells. These findings suggest ceramidase
inhibitors as a potential new therapeutical class of antiproli-
ferative and cytostatic drugs. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Ceramide is a signaling molecule involved in cellular re-
sponses to a variety of apoptotic stimuli [1,2]. It is now evi-
dent that ceramide is involved in the induction of apoptosis,
cell cycle arrest and cell di¡erentiation in various cell systems
[3^5]. Three main metabolic pathways are known to partici-
pate directly in reducing intracellular ceramide levels : (i) bio-
synthesis of sphingomyelin through sphingomyelin synthase,
(ii) biosynthesis of cerebrosides through glycosyltransferases
and (iii) production of sphingosine via ceramidase [6]. Meta-
bolic manipulation of ceramide levels, such as the addition of
bacterial sphingomyelinase or 1-phenyl-2-decanoylamino-3-
morpholino-1-propanol, an inhibitor of glycosylceramide syn-
thases [7], causes accumulation of intracellular ceramide fol-
lowed by ceramide-speci¢c biological responses. Recently,
elevation of endogenous ceramide levels and growth suppres-
sion in HL-60 cells by inhibition of alkaline ceramidase has
been shown [8].
Ceramidases (N-acylsphingosine deacylases) hydrolyze cer-
amide producing sphingosine and a free fatty acid. Three iso-
forms of ceramidases, acid, alkaline and neutral, assigned by
their catalytic pH optimum have been described [9,10]. In
order to evaluate the cellular and biochemical activities of
ceramidase inhibitors we examined the biological e¡ects of
the previously described agents D-erythro-2-N-myristoylami-
no-1-phenyl-1-propanol (D-e-MAPP), its inactive enantiomer
L-erythro-2-N-myristoylamino-1-phenyl-1-propanol (L-e-
MAPP) and a new member of this group, (1R,2R)-2-N-my-
ristoylamino-1-(4-nitrophenyl)-1,3-propandiol (D-NMAPPD).
D-e-MAPP has been recently shown to elevate endogenous
ceramide levels and suppress growth of HL-60 leukemia cells
by inhibition of ceramidase, whereas D-NMAPPD is a novel
member of the ceramidase inhibitor group [8]. Very recently
D-NMAPPD, previously termed B13, has been shown to in-
duce apoptosis in human colon cancer cells in vitro and in
vivo conditions [11]. Our study on HaCaT keratinocytes and
melanoma cells provides evidence that the ceramidase inhib-
itors D-e-MAPP and D-NMAPPD are able to suppress acid
ceramidase activity. The subsequent elevation of the endoge-
nous level of ceramide is followed by induction of apoptosis
and suppression of proliferation in HaCaT keratinocytes.
However, L-e-MAPP, the enantiomer of D-e-MAPP, was with-
out e¡ect. Previously we described a group of human mela-
noma cell populations which are heterogeneously susceptible
to (2S,3R)-N-acetylsphingosine (C2-ceramide)-mediated apo-
ptosis [12]. Treatment of melanoma cells with D-NMAPPD,
but not D-e-MAPP, revealed suppression of acid ceramidase
activity and elevation of endogenous ceramide levels in all
melanoma cell populations. However, induction of apoptosis
and suppression of proliferation succeeded only in ceramide-
sensitive cells, while the ceramide-resistant cells stayed insen-
sitive to D-NMAPPD. On the other hand, Bcl-2 overexpres-
sion abolished apoptosis triggered by D-NMAPPD in HaCaT
keratinocytes and A375 melanoma cells.
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2. Materials and methods
2.1. Materials
D-e-MAPP, L-e-MAPP and D-NMAPPD were synthesized as de-
scribed [13]. N-Palmitoyl-[1-14C]D-sphingosine (55 mCi/mmol) was
purchased from Biotrend (Cologne, Germany) and L-[3H]serine (33
Ci/mmol) was purchased from Amersham (Brunswick, Germany). Re-
maining lipids and detergents were obtained from Sigma (Munich,
Germany). The construction of pIRES/mbcl-2 has been reported pre-
viously and has been shown to be functional in HaCaT keratinocytes
[14] and A375 cells [15].
2.2. Cell culture
The spontaneously immortalized human keratinocyte cell line Ha-
CaT was grown in RPMI medium supplemented with 10% heat-in-
activated fetal calf serum, 0.35 g/l glutamine, 100 IU/ml penicillin and
0.1 g/l streptomycin. Media and culture reagents were obtained from
Biochrom Seromed (Berlin, Germany). Prior to treatment, HaCaT
keratinocytes were cultivated for 24 h in serum-free KGM (Clonetics,
St. Katharinen, Germany). For L-[3H]serine labeling of cells, serine-
free modi¢ed Eagle’s medium (MEM; Biochrom Seromed KG, Ber-
lin, Germany) was used. The applied agents were added to the cells in
KGM. M186 and M221 were obtained from patients with histologi-
cally con¢rmed metastatic melanoma by surgical intervention. A375 is
an established cell line originated from primary tumors [16] and
Mel2A from metastasis [17].
The construction of pIRES/mbcl-2 has been reported previously
and has been shown to be functional in HaCaT keratinocytes [14]
and A375 cells [15].
Brie£y, transfection of melanoma cells and HaCaT keratinocytes
with pIRES1neo/mbcl-2 or pIRES1neo was carried out according to
the supplier’s protocol using the lipofection reagent pFx-2 from In-
vitrogen (Groningen, The Netherlands) and FuGene 6 from Boehr-
inger Mannheim (Mannheim, Germany), respectively. After a selec-
tion period with geneticin of approximately 10 weeks, individual cell
clones were isolated. Bcl-2 overexpression in these cell lines was con-
¢rmed by Western blotting (data not shown).
All melanoma cell populations were grown and treated in Dulbec-
co’s MEM (Gibco BRL, Karlsruhe, Germany) supplemented with
10% fetal calf serum and 100 IU/ml penicillin and 0.1 g/l streptomy-
cin.
2.3. Determination of cytotoxicity
Cytotoxicity was determined with the cytotoxicity detection kit (lac-
tate dehydrogenase, LDH) from Roche Diagnostics (Mannheim, Ger-
many) exactly as described elsewhere [5].
2.4. Cell death detection
Subcon£uent cells in 24-well plates were treated with the indicated
agents or respective control vehicle. After incubation, cell death was
measured in a photometric enzyme immunoassay for the qualitative
and quantitative in vitro determination of cytoplasmic histone-asso-
ciated DNA fragments (mono- and oligonucleosomes) with the kit
‘Cell death detection ELISAPLUS’ from Roche Diagnostics as de-
scribed elsewhere [18].
2.5. Cell proliferation assay
HaCaT keratinocytes and melanoma cells were seeded in 24-multi-
well plastic culture dishes and treated with the respective agents or
control vehicle at 40% con£uence. After incubation, cell proliferation
was determined by crystal violet staining as described in detail [19].
2.6. Measurement of ceramidase activity in HaCaT keratinocytes and
melanoma cells
Ceramidase activity was measured by a modi¢cation of the method
of Gatt and Yavin [20] and Sugita [21]. Cells were disrupted by ho-
mogenization in a Dounce homogenizer and subsequent sonication in
0.25 M sucrose, 1 mM EDTA, 1 mM sodium vanadate, 1 mM phen-
ylmethylsulfonyl £uoride, 1 mM CaCl2 and 20 Wg/ml of each leupep-
tin, pepstatin and aprotinin. Protein was measured in samples by the
BCA assay [22]. Substrate solution was prepared by combining 1.5 Wl
10 WCi/ml N-palmitoyl-[1-14C]D-sphingosine, 2.5 Wl 1 mM N-stearoyl-
D-sphingosine, 25 Wl 0.1% Triton X-100 (v/v) in chloroform/methanol,
2:1 (v/v) and 25 Wl 0.2% sodium cholate (w/v) in chloroform/metha-
nol, 2:1 (v/v). Solvents were evaporated, resolved in 7.5 Wl H2O,
sonicated for 3 min, heated for 5 s at 80‡C and cooled rapidly on
ice. Then, to 25 Wl of the cell extract 5 Wl of 50 mM MgCl2, 7.5 Wl of
substrate solution and 12.5 Wl of one of the respective bu¡ers were
added. For measurement of alkaline ceramidase, 0.2 M CHES, pH 9.0
and for acid ceramidase 0.2 M sodium acetate, pH 4.5 were used.
Ethanol, the solvent of the inhibitors, had no e¡ect on the enzyme
reaction. The reaction mixture was incubated for 1 h at 37‡C. The
[14C]palmitic acid product of ceramidase was isolated by the addition
of 0.5 ml of isopropyl alcohol/heptane/1 M NaOH (40:10:1, v/v/v),
0.3 ml of heptane and 0.25 ml of H2O. Samples were mixed and
centrifuged for 5 min at 13 000Ug at 4‡C. The upper phase was
discarded and the lower phase washed twice with heptane. Finally,
0.25 ml of 0.5 M H2SO4 and 0.5 ml of heptane were added and after
mixing and centrifugation, the upper phase was used for counting by
liquid scintillation.
2.7. Measurement of ceramide levels
Cells were seeded in six-well plates and, after reaching a subcon-
£uent state, metabolically labeled with 2 WCi/ml L-[3H]serine in serine-
free MEM medium for 24 h to reach steady-state conditions [23].
Subsequently, chasing for 3 h with 5 mM non-radioactive serine in
KGM was performed, followed by treatment with agents or respective
vehicle as indicated. Lipids were extracted as described [24]. The ex-
tracted lipids were diluted in 50 Wl chloroform/methanol, 9:1 (v/v) and
20 Wl of this solution was applied to precoated silica gel 60 high per-
formance thin layer chromatography plates (Merck, Darmstadt, Ger-
many) and developed in chloroform/methanol, 9:1 (v/v). The quanti-
¢cation of ceramide contents was achieved by scanning of
autoradiographs using an imaging densitometer (Bio-Rad, Munich,
Germany) and analyzed using MultiAnalyst Software (Bio-Rad).
3. Results
3.1. D-e-MAPP and D-NMAPPD inhibit the activity of acid
ceramidase
Since earlier studies of D-e-MAPP and L-e-MAPP in HL-60
cells showed an inhibitory e¡ect of D-e-MAPP but not L-e-
MAPP on alkaline ceramidase, we examined the e¡ect of
these compounds and their analogue D-NMAPPD on acid
as well as alkaline ceramidase isoforms. Ceramidase activity
was examined for pH dependence using 14C-labeled C16-cer-
amide as substrate in cytosolic and membrane fractions of
HaCaT keratinocytes and melanoma cells. The pH optima
of ceramidase activity was found to exist at pH 4.5 and pH
9.0 as described for HL-60 cells [8]. D-e-MAPP served as a
relatively poor inhibitor of acid ceramidase in a concentra-
tion-dependent manner in HaCaT keratinocytes, with an ap-
proximately half-inhibitory concentration of 500 Wmol/l
(IC50 = 500 WM). In contrast D-NMAPPD was found to be a
potent inhibitor of acid ceramidase with an IC50 of about 10
Wmol/l. These results demonstrate that D-NMAPPD is a much
more potent inhibitor of acid ceramidase activity than D-e-
MAPP in HaCaT keratinocytes (Fig. 1A). D-NMAPPD at a
concentration of 500 Wmol/l reduced the alkaline ceramidase
activity only to 90% and in contrast the acid ceramidase ac-
tivity to 18% compared to control in all investigated cells.
D-NMAPPD served as a strong inhibitor of acid ceramidase,
while alkaline ceramidase activity was inhibited marginally by
D-NMAPPD (Fig. 1B) and D-e-MAPP (data not shown). L-e-
MAPP inhibited neither acid nor alkaline ceramidase up to
concentrations of 500 Wmol/l (data not shown).
3.2. Only high concentrations of D-NMAPPD have signi¢cant
cytotoxic e¡ects on HaCaT and melanoma cells
Cells were treated with indicated concentrations of
D-NMAPPD, D-e-MAPP or L-e-MAPP. After 12 h of incuba-
tion, cytotoxicity was detected by a measurement of the re-
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lease of LDH activity into the cell culture supernatants. No
signi¢cant LDH-release was observed when cells were incu-
bated with 25 or 50 WM of D-e-MAPP (Fig. 2), indicating that
membrane integrity was not impaired in this case. Also 25 WM
D-e-NMAPPD was without any cytotoxic e¡ect, whereas 50
WM D-NMAPPD increased the rate of LDH-release up to
210% of control in all investigated cells (Fig. 2, inset). L-e-
MAPP as the stereoisomer of D-e-MAPP was without any
e¡ect at both concentrations.
3.3. Elevation of endogenous ceramide levels upon treatment
with D-NMAPPD
After radiolabeling with L-[3H]serine of HaCaT keratino-
cytes and melanoma cells for 24 h, cells were treated with
25 WM D-e-MAPP, D-NMAPPD or ethanol vehicle for various
periods of time. An eight-fold ceramide elevation was ob-
served in HaCaT keratinocytes already after 3 h of treatment
and a maximum of 11-fold after 6 h of treatment with
Fig. 1. Concentration-dependent e¡ect of D-e-MAPP and D-
NMAPPD on acid ceramidase activity in HaCaT keratinocytes (A)
and the e¡ect of D-NMAPPD on activity of acid and alkaline ce-
ramidases in HaCaT keratinocytes and melanoma cells (B). In vitro
activity of these enzymes was detected as described in Section 2. Us-
ing N-palmitoyl-[1-14C]-D-sphingosine as substrate, solubilizates of
cells were incubated for 60 min at the respective pH (acid cerami-
dase activity, pH 4.5; alkaline ceramidase activity, pH 9.0). (A)
Represents acid ceramidase activity in the presence of D-e-MAPP
and D-NMAPPD in HaCaT keratinocytes. (B) Represents activity
of alkaline ceramidase (a) and acid ceramidase (b) in the presence
of 500 WM D-NMAPPD in HaCaT keratinocytes and melanoma cell
populations A375, M186, Mel2A and M221. Values are given as
percent of control þ S.D. (n = 4).
Fig. 2. Concentration-dependent cytotoxic e¡ects of ceramidase in-
hibitors. Subcon£uent HaCaT keratinocytes and A375, M186,
Mel2A and M221 cell populations were treated with di¡erent con-
centrations of D-e-MAPP and D-NMAPPD (see inset). After 12 h of
incubation, cytotoxicity was determined as described in Section 2.
Values are given as percent of control þ S.D. (n = 4).
Fig. 3. In£uence of D-NMAPPD on endogenous ceramide levels in
HaCaT keratinocytes and melanoma cells. Subcon£uent HaCaT ker-
atinocytes and the melanoma cell populations A375, M186, Mel2A
and M221 were radiolabeled with L-[3H]serine for 24 h. Then, cells
were treated with vehicle or with 25 WM D-e-MAPP and D-
NMAPPD. Lipids were extracted for ceramide measurements at the
indicated time points as described in Section 2. A: Time-dependent
increase of endogenous ceramide in HaCaT keratinocytes. B: Cer-
amide increase in HaCaT keratinocytes and melanoma cell lines
after treatment with D-NMAPPD or vehicle control for 24 h. Values
are given as percent of control þ S.D. (n = 3).
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D-NMAPPD. A continuous ceramide increase was seen in
HaCaT keratinocytes after treatment with D-e-MAPP, reach-
ing a maximum of six-fold after 24 h (Fig. 3A). Moreover,
treatment of four melanoma cell lines with 25 WM
D-NMAPPD for 24 h resulted in a strong accumulation of
ceramide (Fig. 3B) reaching more than nine-fold as compared
to vehicle-treated cells.
3.4. Ceramidase inhibitors inhibit cell proliferation
After 48 h of incubation with the respective substances, the
cell proliferation was measured. In a concentration-dependent
manner in HaCaT keratinocytes, the most potent inhibitor of
cell proliferation was D-NMAPPD with an IC50 of about
7 WM, whereas D-e-MAPP showed reduced antiproliferative
activity. Cell growth was inhibited by only 40% at a concen-
tration of s 10 WM D-e-MAPP (Fig. 4A). Two ceramide-sen-
sitive melanoma cell populations (A375, M186) and two cer-
amide-resistant melanoma cells (Mel2A, M221) were treated
for 48 h with 25 WM D-NMAPPD. D-NMAPPD reduced cell
numbers in a concentration-dependent manner in ceramide-
sensitive melanoma cell populations. In contrast, D-NMAPPD
showed no antiproliferative e¡ect on ceramide-resistant mela-
noma cells (data not shown). D-e-MAPP exhibited no antipro-
liferative e¡ect on melanoma cell lines and 25 WM L-e-MAPP
was also without antiproliferative e¡ect on HaCaT keratino-
cytes and melanoma cells. In a long time course proliferation
experiment, the number of A375 melanoma cells decreased
continuously and after 7 days of treatment with 25 WM
D-NMAPPD was reduced to 18% (Fig. 4B).
3.5. Ceramidase inhibitors induce apoptosis in HaCaT and
melanoma cells
We tested the ability of D-e-MAPP, L-e-MAPP and D-
NMAPPD to induce apoptosis in keratinocytes and melano-
ma cells. HaCaT keratinocytes, two ceramide-sensitive (A375,
M186) and two ceramide-resistant (Mel2A, M221) melanoma
cell populations were treated for 24 h with 25 WM D-e-MAPP,
D-NMAPPD or L-e-MAPP. Apoptosis was determined mor-
phologically by observation under light microscopy and mea-
sured photometrically using an enzyme immunoassay. D-
NMAPPD was a very e⁄cient proapoptotic stimulus and
the rate of D-NMAPPD-treated HaCaT keratinocytes driven
into apoptosis was 7.5-fold compared to control cells incu-
bated with ethanol as a control vehicle. D-NMAPPD also
induced apoptosis in the two ceramide-sensitive melanoma
cell populations, A375 and M186. The rate of apoptotic
A375 melanoma cells after treatment was 3.5-fold and that
of apoptotic M186 melanoma cells was three-fold compared
to vehicle-treated cells. In contrast, D-NMAPPD showed no
apoptotic e¡ect on ceramide-resistant melanoma cells. D-e-
MAPP had no proapoptotic e¡ects on all melanoma cell lines,
whereas cell death rates of HaCaT keratinocytes after treat-
ment with 25 WM D-e-MAPP was two-fold compared to con-
trol (data not shown). L-e-MAPP, the inactive enantiomer,
was without apoptotic e¡ect in all tested cell lines at a con-
centration of 25 WM.
Fig. 4. Concentration-dependent antiproliferative e¡ects of cerami-
dase inhibitors on HaCaT keratinocytes and melanoma cells. Cell
growth was measured photometrically using DNA staining with
crystal violet as described in Section 2. A: Subcon£uent HaCaT
keratinocytes were treated with non-cytotoxic concentrations of D-e-
MAPP and D-NMAPPD for 48 h. B: Long time course prolifera-
tion experiment with A375 melanoma cells upon treatment with 25
WM D-NMAPPD. Values are given as percent of control þ S.D.
(n = 4).
Fig. 5. The involvement of Bcl-2 in D-NMAPPD-induced apoptosis.
Bcl-2 transfected A375 melanoma cells and HaCaT keratinocytes
and respective vector transfected cells were treated with 25 and 50
WM D-NMAPPD for 24 h. The inset shows cytotoxicity measured in
the same cell lines as above under the in£uence of 50 WM D-
NMAPPD after 12 h. DNA fragmentation and cytotoxicity were
measured as described in Section 2. DNA fragmentation or cytotox-
icity of control cells was set as 100% and DNA fragmentation or
cytotoxicity of treated cells was calculated as % of control. Values
represent the mean of three experiments þ S.D.
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3.6. Overexpression of Bcl-2 prevents D-NMAPPD-triggered
apoptosis
Ceramide-induced cytochrome c release has been shown to
be prevented by Bcl-2 overexpression. In order to further elu-
cidate the role of ceramidase inhibitors in our experimental
model, we used Bcl-2 overexpressing HaCaT keratinocytes
and A375 melanoma cells published recently [14,15]. Bcl-2
overexpression completely abolished apoptosis induced by
25 WM D-NMAPPD, suggesting that the apoptosis induced
by elevation of endogenous ceramide through inhibition of
acid ceramidase activity is a mitochondrial activation-depen-
dent process (Fig. 5). Bcl-2 overexpression also abolished ap-
optosis induced by 50 WM D-NMAPPD but not the cytotoxic
e¡ects of this concentration (Fig. 5, inset). The distinction
between apoptotic and cytotoxic e¡ects demonstrates that
the apoptosis induced by D-NMAPPD is independent of its
cytotoxicity in melanoma cells.
4. Discussion
We examined the cellular response to the ceramidase inhib-
itors, D-e-MAPP and its new analogue D-NMAPPD, in Ha-
CaT keratinocytes and human melanoma cells.
In the ¢rst step, we investigated the in£uence of these com-
pounds on the ceramidase activity and endogenous ceramide
levels. Our experiments with D-e-MAPP and D-NMAPPD re-
vealed inhibition of acid ceramidase in all investigated cell
lines (D-NMAPPD served as a stronger inhibitor than D-e-
MAPP), while the alkaline isoform was a¡ected only slightly.
These results are in contrast to previously published ¢ndings
in HL-60 cells, where D-e-MAPP inhibited the acid ceramidase
marginally (IC50s 500 WM) but activity of alkaline cerami-
dase was completely abolished by an IC50 of 1^5 WM. By
quantitative evaluation of ceramide content, we demonstrated
an increase of the ceramide pool which was in accordance
with the decrease of acid ceramidase activity. Furthermore,
D-e-MAPP displayed a less antiproliferative and apopotic ef-
fect than D-NMAPPD in HaCaT keratinocytes. Moreover, it
did not show any e¡ect in melanoma cells, while D-NMAPPD
signi¢cantly in£uenced both HaCaT and melanoma cells.
Therefore, we suggest that D-NMAPPD is a more potent ce-
ramidase inhibitor than D-e-MAPP strongly inhibiting the
acid isoenzyme. A major di¡erence between D-e-MAPP and
D-NMAPPD is the presence of a hydroxyl group in a position
corresponding to the 1-hydroxyl group of ceramide. This
group may be responsible for substrate recognition of ceram-
idases and therefore it can lead to an increased binding of the
inhibitor. Recently, we identi¢ed a group of human melanoma
cell populations which are heterogenously susceptible to cer-
amide-mediated apoptosis paralleled by a low relative Bax to
Bcl-2 protein ratio [15]. D-NMAPPD induced apoptosis in
ceramide-sensitive melanoma cells, while the ceramide-resis-
tant melanoma cells were insensitive to D-NMAPPD, thus
con¢rming the e¡ect of this inhibitor on the ceramide signal-
ing pathway. Furthermore, Bcl-2 overexpression abolished ap-
optosis triggered by D-NMAPPD in HaCaT keratinocytes and
A375 melanoma cells, pointing out the involvement of mito-
chondrial activation and cytochrome c release in D-
NMAPPD-induced apoptosis.
The acid isoenzyme of ceramidase is predominantly local-
ized in lysosomes and has been previously described mainly in
connection with biodegradation of sphingolipid metabolites,
most likely in the process of recycling membrane lipids
through the lysosomal pathway. On the other hand, alkaline
and neutral ceramidases have been described to be involved in
sphingosine-mediated signal transduction pathways in eukary-
otic cells [8]. Here, we demonstrate the capability of regulating
endogenous ceramide levels through modulation of acid ce-
ramidase activity. This elevation of intracellular ceramide has
signi¢cant biological consequences in vitro and mimicks the
e¡ects obtained upon treatment with exogenous ceramides [5].
Therefore, we suggest that the action of exogenous cell-per-
meable ceramides elevates the cellular ceramide pool and can
serve as an appropriate tool for studying ceramide biology.
The signi¢cance of lysosomal pool of ceramide in signaling
processes has been a matter of controversial debate [25]. With
regards to the intracellular accumulation of ceramide, Se¤gui et
al. [26] have shown that elevated ceramide levels in acidic
compartments neither a¡ect cell growth nor the susceptibility
of cells to apoptotic stimuli. This explains why ¢broblasts
having a genetic defect in acid ceramidase activity (Farber
disease) and therefore accumulating ceramide in lysosomes
do not display any abnormality in cell viability. On the other
hand, Strelow et al. [27] clearly demonstrate the involvement
of acidic ceramidase in apoptosis where mostly lysosomal cer-
amide is depleted. Overexpression of this enzyme protects
from tumor necrosis factor K (TNFK)-induced cell death. Fur-
thermore, other studies involving acidic sphingomyelinase (aS-
Mase) have shown that the acidic compartment does indeed
play an important role in signal transduction. TNFK signaling
was shown to activate aSMase and therefore to involve lyso-
somes which could further be con¢rmed by using the lysoso-
motropic agent NH4Cl and the vesicularization inhibitor bre-
feldin A [28,29]. Additionally, several recent papers show that
aSMase can be secreted and can also be targeted to speci¢c
plasma membrane microdomains rich in sphingolipids, such
as caveolae and rafts [30^32]. The targeting of aSMase re-
quires di¡erent N-terminal proteolytic cleavages and glycosyl-
ation events [33]. It is conceivable that a similar mechanism
might also exist for the acidic ceramidase.
Our ¢ndings provide an important insight into the physio-
logic signi¢cance of regulating ceramide metabolism and sug-
gest ceramidase inhibitors as a new class of compounds for
the treatment of hyperproliferative skin diseases.
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